Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Osimertinib · 1 trial · 4 indications
Progression free survival (PFS) time will be calculated from the date of randomization to disease progression or death from any cause, whichever occurs the first.
| Arm | Type | Description |
|---|---|---|
| Arm A (Osimertinib and Ramucirumab) | ACTIVE_COMPARATOR | Osimertinib and Ramucirumab |
| Arm B (Osimertinib) | ACTIVE_COMPARATOR | Osimertinib |
| Name | Type | Description |
|---|---|---|
| Osimertinib | DRUG | Osimertinib 80 mg orally on Day 1 |
| Ramucirumab | DRUG | Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes |
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. * Age ≥ 18 years at the time of consent. * Histologically or cytological...
Top 20 of 86 competitors